ArticleInfection2026
Sustaining herd immunity against measles: Insights from a serological cohort study in an outbreak-free population.
Article in Infection, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeMeasles antibody levels decline after MMR vaccination, raising concerns about individual protection and maintenance of herd immunity. In Finland, MMR vaccinations started in 1982, and only sporadic measles cases have been observed since the late 1980s. This suggests that a high proportion of individuals are unlikely to transmit measles. We examine the sustainability of herd immunity by inferring the antibody threshold sufficient to interrupt measles transmission.
methodsWe utilized measles antibody data collected after the second MMR vaccine dose from 157 individuals in a Finnish MMR-vaccinated cohort at 8 sampling rounds during 1987-2012 (ages 6-31 years), with antibody concentrations measured using the haemagglutination inhibition assay and/or enzyme immunoassay depending on the round. Antibody decline after vaccination was estimated and extrapolated beyond the study age range to predict the proportion exceeding candidate antibody thresholds in the 2022 Finnish population. Threshold sufficiency was evaluated by comparing this proportion with the critical proportion required to sustain the absence of measles epidemics.
resultsThe mean follow-up time was over 20 years, with 68% of all potential samples available. After age 13, antibody levels declined slowly or very slowly, with first and second half-lives of 10 and 20, or 22 and 67 years, respectively. No unique threshold was identified. However, the continued absence of measles epidemics suggests a very slow decline and/or a low (< 120 mIU/ml) antibody threshold to interrupt transmission.
conclusionsVaccine-induced protection against measles transmission appears long-lasting. For herd immunity, declining vaccine uptake poses a greater risk than waning immunity.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.